PCRX Pacira BioSciences Inc.

43.56
+0.44  (+1%)
Previous Close 43.12
Open 43.3
Price To Book 5.49
Market Cap 1,798,894,576
Shares 41,296,937
Volume 492,382
Short Ratio
Av. Daily Volume 614,413

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 31, 2011.
EXPAREL
Postsurgical pain
Approval announced April 6, 2018.
EXPAREL
Post surgical pain

Latest News

  1. Pacira BioSciences Announces Validation of EXPAREL Marketing Authorization Application from European Medicines Agency
  2. Is Pacira BioSciences, Inc. (NASDAQ:PCRX) Trading At A 36% Discount?
  3. JAZZ or PCRX: Which Is the Better Value Stock Right Now?
  4. Pacira BioSciences Appoints Former Johnson & Johnson Executive, Max Reinhardt, as President
  5. See what the IHS Markit Score report has to say about Pacira Biosciences Inc.
  6. Edited Transcript of PCRX earnings conference call or presentation 2-May-19 12:30pm GMT
  7. New Analysis Shows Use of EXPAREL Associated with Improved Clinical and Economic Outcomes Following Hip Replacement Surgery
  8. Pacira Announces Publication of Pivotal Study of EXPAREL as a Single-Dose Interscalene Brachial Plexus Nerve Block in Patients Undergoing Shoulder Surgery
  9. Why Is Pacira (PCRX) Down 7.2% Since Last Earnings Report?
  10. Cara Shares Up on Positive Phase III Data for Itchiness Drug
  11. Pacira BioSciences to Present at the Jefferies 2019 Healthcare Conference
  12. How Financially Strong Is Pacira BioSciences, Inc. (NASDAQ:PCRX)?
  13. JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?
  14. Pacira BioSciences to Present at Two Healthcare Conferences in May
  15. Phase 4 Study Demonstrates Superiority of EXPAREL plus Bupivacaine versus Bupivacaine Alone in Cesarean Section Procedures
  16. Pacira Pharmaceuticals, Inc. (PCRX) Q1 2019 Earnings Call Transcript
  17. Pacira BioSciences Rocks in Q1 With Strong Momentum for Pain Drug Exparel
  18. Pacira (PCRX) Misses Q1 Earnings Estimates